The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a clinical trial run by the American Society of Clinical Oncology (ASCO), the world’s leading professional organization representing physicians who care for people with cancer. The TAPUR Study is a clinical trial focused on targeted therapies for people with later-stage cancer.
Targeted therapy is a cancer treatment that uses drugs to help stop cancer from growing and spreading. Targeted drugs work by targeting specific genes or proteins that help tumors grow. Because each targeted therapy works only when the cancer has a specific genetic change, or mutation, the researchers involved in the TAPUR study hope to find out if drugs currently available for some cancers can also be used to treat other cancers with the same targets.
In this podcast, TAPUR principal investigator Richard L. Schilsky, MD, FACP, FASCO, gives an overview of the study and what has been learned since it launched in 2016.
- What challenges with cancer care does the TAPUR Study seek to address? [01:56]
- How does the TAPUR Study work? [03:22]
- What is ASCO doing with the research findings? [05:02]
- What is an example of a targeted therapy being studied on new types of cancer? [05:27]
- Where can people with cancer learn more about the TAPUR Study and how to participate? [07:21]
- How is this research helping people with later-stage cancer and the cancer care community? [08:39]
Dr. Richard L. Schilsky is the former Chief Medical Officer of ASCO (2013 to 2021) and a highly respected leader in the field of clinical oncology. Formerly the Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center, he specializes in new drug development and treatment of gastrointestinal cancers. View Dr. Schilsky’s disclosures.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
